0

Discovery of N-isoxazolyl Biphenylsulfonamides as Potent Dual Angiotensin II and Endothelin A Receptor Antagonists

Natesan Murugesan, John E Tellew, Zhengxiang Gu, Bridgette L Kunst, Leena Fadnis, Lyndon A Cornelius, Rose Ann F Baska, Yifan Yang, Sophie M Beyer, Hossain Monshizadegan, Kenneth E Dickinson, Balkrushna Panchal, etc.

J Med Chem. 2002 Aug 29;45(18):3829-35.

PMID: 12190306

Abstract:

The ET(A) receptor antagonist (2) (N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-[1,1'-biphenyl]-2-sulfonamide, BMS-193884) shares the same biphenyl core as a large number of AT(1) receptor antagonists, including irbesartan (3). Thus, it was hypothesized that merging the structural elements of 2 with those of the biphenyl AT(1) antagonists (e.g., irbesartan) would yield a compound with dual activity for both receptors. This strategy led to the design, synthesis, and discovery of (15) (4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(3,4-dimethyl-5-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-[1,1'-biphenyl]-2-sulfonamide, BMS-248360) as a potent and orally active dual antagonist of both AT(1) and ET(A) receptors. Compound 15 represents a new approach to treating hypertension.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP254737876 BMS-248360 BMS-248360 254737-87-6 Price
qrcode